Bernardo Arrospide is senior operating associate with the Accel-KKR Consulting Group and is focused on the Latin America and Iberia region.

Prior to joining Accel-KKR, Bernardo was the co-founder and CEO of 4Vets, a venture-backed supply chain and procurement software business for the veterinary pharmaceutical industry in Brazil.  Bernardo was also previously the Chief of Staff to the CEO of the Medicines Company, a publicly traded biotech company acquired by Novartis in 2019 for $9.7bn USD.  While at the Medicines Company Bernardo led the company’s Latin America expansion strategy.  Bernardo started his career in Investment Banking at Goldman Sachs where he worked in both the New York and London offices.

Bernardo is involved with Accel-KKR’s investments in imed, Siigo, Lemontech and Endalia.

Bernardo received his M.B.A. with a specialization in Healthcare Management from the Wharton School, and his A.B. in Economics from the University of Chicago.